Quintiles Announces Clinical Research Partnership with the University Malaya Medical Centre
Quintiles has announced a strategic alliance agreement with the University Malaya Medical Centre (UMMC) as part of its Prime Site program - an initiative focused on accelerating the development of new and effective medicines.
The UMMC is the first Prime Site in Asia for Quintiles, adding to its existing four other sites located in the United States, Europe and Africa.
“Prime Sites are large clinical institutions that collaborate with Quintiles to enhance their infrastructure for conducting clinical trials.”
"Prime Sites are large clinical institutions that collaborate with Quintiles to enhance their infrastructure for conducting clinical trials," explained Christopher Cabell M.D. "The University Malaya Medical Centre is an ideal partner for us because of its experience in conducting clinical research, its access to substantial patient populations and its clinical expertise across multiple therapeutic areas. Through this new alliance, Quintiles will be able to significantly improve its reach to patients and investigators who are critical to facilitating the increasingly complex therapies under development."
Professor Dato' Ikram Shah bin Ismail, Director of the University Malaya Medical Centre said, "We take great pride in being recognized as a remarkable institution for our long-term commitment and experience in conducting safe and international-caliber clinical research, our clinical expertise across multiple therapeutic areas, and our capability to access a large pool of patients. We believe that this partnership with Quintiles will serve as an impetus for UMMC to achieve greater efficiencies in conducting clinical trials. By enhancing the efficacy, productivity and quality of clinical research at UMMC, we will ultimately propel the advancement of medical practice in improving human health."
Anand Tharmaratnam, M.D., Senior Vice President and Head of Clinical Development for Quintiles Asia-Pacific said, "Malaysia is an increasingly important player in Asia-Pacific clinical drug development and the commitment of its government, academic and private industry leaders to promoting leading-edge clinical research in the country is undeniable. This, coupled with the highly skilled clinical workforce, strong clinical research infrastructure and large potential patient populations makes Malaysia and UMMC a quality fit as our first Prime Site in Asia. With the enthusiasm and vision for this model that our UMMC partner has shown, we are confident that this will serve as a strong foundation for our Prime Site program in Asia."